Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal of Health Management and Pharmacy Exploration (JOHMPE)
Istiqomah, Dyah Fatha
Unknown Affiliation
Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Effectiveness and safety of the monoclonal antibody drug lecanemab (Leqembi) in reducing beta-amyloid plaques in alzheimer's dementia: a literature review Meidina, Adinda Nezma; Ramadhanti, Nafilah; Istiqomah, Dyah Fatha; Putri, Yolanda Delia; Hasibuan, Nabila Az-zahra
Journal of Health Management and Pharmacy Exploration Vol. 3 No. 1 (2025): February 2025
Publisher : Surya Hijau Manfaat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52465/johmpe.v3i1.547

Abstract

Dementia is a syndrome characterized by cognitive decline, behavioral changes, and impaired self-care, with Alzheimer's disease (AD) being the most common cause. The global prevalence of AD is rising and is expected to reach 152 million cases by mid-century, imposing significant public health and economic burdens, particularly in low- and middle-income countries. AD is marked by synapse loss and neuronal atrophy, beginning in the hippocampus and spreading across the cerebral cortex due to β-amyloid plaque and neurofibrillary tangle accumulation, which disrupt neuronal communication and survival. Current treatments, such as memantine and cholinesterase inhibitors, provide only temporary symptom relief without stopping disease progression. Literature was searched using search engines such as Google Scholar, Science Direct, ResearchGate, and NCBI. Inclusion and exclusion criteria were applied, resulting in 27 relevant references that explored monoclonal antibody-based therapies and multidisciplinary interventions for AD management. Lecanemab has been shown to reduce amyloid accumulation effectively. However, its use is associated with risks such as amyloid-related imaging abnormalities with edema (ARIA-E) and hemorrhage ARIA-H, particularly in ApoE ε4 carriers. Despite these concerns, recent meta-analyses suggest that lecanemab is generally well-tolerated and offers potential as a cost-effective treatment for AD. Monoclonal antibody therapies, such as lecanemab, provide hope for slowing AD progression. Further research is crucial for developing more effective treatments. A multidisciplinary approach that integrates pharmacological therapies with advanced technologies may offer a more effective strategy for managing AD in the future.
Co-Authors Hasibuan, Nabila Az-zahra Meidina, Adinda Nezma Putri, Yolanda Delia Ramadhanti, Nafilah